Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Authors' conclusion
GLP-1RA and SGLT2i use in T1DM is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful patient selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.
Study context
- Population
- Adults with T1D who used a GLP-1 RA and/or SGLT2i for >90 days, single academic center
- Participants
- 76 vs 39
- Exposure
- GLP-1 RA vs SGLT2i as adjuncts to insulin in T1D
- GLP-1RAn = 76
- SGLT2in = 39
- Outcome
- Change after 1 year of therapy
- Follow-up
- 1 year
Methodological detailsretrospective chart review, single academic center, real-world
- Retrospective chart review
- Single academic center
- Real-world
Main finding
As reported in the abstract
- GLP-1RA: weight 90.5 kg to 85.4 kg
- P < .001
- GLP-1RA: Hemoglobin A1c (HbA1c) 7.7% to 7.3%
- P = .007
- GLP-1RA: total daily insulin dose 61.8 units to 41.9 units
- P < .001
- SGLT2i: HbA1c 7.9% to 7.3%
- P < .001
- SGLT2i: basal insulin 31.3 units to 25.6 units
- P = .003
Observational data: associations, not effects.
Safety
DKA · mean total duration of use 29.5 months/patient
Discontinuation due to adverse events · % of the time
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study. J Clin Endocrinol Metab. Published 21 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →